Work

CLO25-058: First-in-Human, Multicenter Phase 1 Study of the Bromodomain 2 Inhibitor ABBV-744 in Relapsed/Refractory Acute Myeloid Leukemia

Year: 2025

Type: article

Source: Journal of the National Comprehensive Cancer Network

DOI: 10.6004/jnccn.2024.7122

Authors: Anjali Advani, Olatoyosi Odenike, Deepa Jeyakumar, Raya Mawad, Olga Frankfurt, Jiuhong Zha, Jason G. Harb, Minh H. Dinh, Brian Jonas, Courtney D. DiNardo

Institutions: Cleveland Clinic, University of Chicago, University of California, Irvine, Swedish Medical Center, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, AbbVie (United States), University of California, Davis, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Protein Degradation and Inhibitors

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4408939844

FWCI: 0.261

Cites:

Cited by: 1

Related to: 10